All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
CD7-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated high complete remission (CR) rates in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma (T-ALL/LBL). The impact of CD7-directed CAR T-cells on transplantation outcomes in this patient population is currently unknown.1
Here, we summarize a retrospective study published by Cao et al.1 in British Journal of Haematology on the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with R/R T-ALL/LBL who achieved a CR after CD7-directed CAR T-cell therapy.1
Figure 1. 2-year OS, LFS, NRM, and RI between CD7 CAR T-cell and chemotherapy groups*
CAR, chimeric antigen receptor; LFS, leukemia-free survival; NRM, non-relapse mortality; OS, overall survival; RI, relapse incidence.
*Data from Cao, et al.1
Key learnings |
|
Your opinion matters
Subscribe to get the best content related to ALL delivered to your inbox